Log in
Inactivated viral vaccine

Polio vaccine

Polio vaccine is an immunizing agent available as inactivated (IPV) or live attenuated oral (OPV) formulations that prevent poliomyelitis caused by poliovirus types 1, 2, and 3. IPV is the standard in most developed countries including the US, while OPV is used in mass immunization campaigns in endemic regions. The most testable fact is that OPV can cause vaccine-associated paralytic poliomyelitis (VAPP) in approximately 1 in 2.4 million doses, whereas IPV cannot.

Practice questionsHigh-yield facts
Drug classInactivated viral vaccine (IPV) or live attenuated (OPV)
MechanismInduces humoral immunity against poliovirus types 1, 2, 3
Main usesPrevention of poliomyelitis in routine childhood immunization schedules
Key adverse effectVAPP with OPV; local reactions with IPV
9 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Polio vaccine induces active immunity against poliovirus by stimulating the production of neutralizing antibodies. Two formulations exist with distinct mechanisms:

Inactivated Polio Vaccine (IPV) contains formalin-inactivated poliovirus types 1, 2, and 3. After intramuscular or subcutaneous injection, IPV induces humoral immunity by stimulating IgG antibody production. These circulating antibodies prevent viremia and central nervous system invasion, thereby preventing paralytic disease. IPV produces excellent systemic immunity but limited mucosal immunity in the gastrointestinal tract.

Oral Polio Vaccine (OPV) contains live attenuated strains of poliovirus types 1, 2, and 3 (trivalent OPV, or monovalent/bivalent forms in some campaigns). After oral administration, the attenuated virus replicates in the gastrointestinal tract, inducing both humoral (IgG) and mucosal (secretory IgA) immunity. The mucosal immunity reduces viral shedding and provides herd immunity by limiting transmission. However, the attenuated virus can rarely revert to neurovirulence, causing vaccine-associated paralytic poliomyelitis.

Both vaccines target the poliovirus capsid proteins, inducing type-specific immunity that prevents infection by wild-type poliovirus strains.

High-yield for exams
  • OPV can cause vaccine-associated paralytic poliomyelitis (VAPP) in ~1 per 2.4 million doses; IPV cannot cause polio because virus is inactivated
  • OPV induces mucosal (IgA) and systemic (IgG) immunity; IPV induces primarily systemic immunity with limited mucosal protection
  • OPV is contraindicated in immunocompromised patients and their household contacts due to VAPP risk; use IPV instead
  • IPV is the vaccine of choice in the US and developed countries; OPV is used in endemic regions for eradication campaigns
  • Vaccine-derived poliovirus (VDPV) can emerge when OPV virus mutates in under-immunized populations, causing outbreaks
  • Adult travelers to polio-endemic countries (Afghanistan, Pakistan) should receive a one-time IPV booster if previously vaccinated
  • IPV can be given safely during pregnancy if indicated; OPV should be avoided but inadvertent administration is not harmful
  • Both vaccines provide lifelong immunity after complete primary series; routine adult boosters are not needed except for travel/occupational exposure

Indications

Polio vaccine is indicated for active immunization against poliomyelitis in infants, children, and adults.

Routine immunization

  • IPV is the vaccine of choice in the United States and most developed countries for routine childhood immunization, administered according to the recommended schedule
  • Primary series consists of multiple doses administered beginning in early infancy
  • Recommended for all children unless contraindicated

Catch-up immunization

  • Unvaccinated or incompletely vaccinated children and adults
  • Refugees and immigrants from polio-endemic or outbreak areas

Travel

  • Adults traveling to polio-endemic countries or areas with active outbreaks who have completed primary series may receive a single lifetime booster dose of IPV
  • Previously unvaccinated adults traveling to endemic areas should receive accelerated primary series

Special populations

  • Healthcare workers with potential exposure to poliovirus
  • Laboratory workers handling specimens that may contain poliovirus

Mass immunization campaigns

  • OPV is used in some countries for mass immunization campaigns and outbreak response due to ease of administration, lower cost, and induction of mucosal immunity that interrupts transmission
  • OPV is contraindicated in immunocompromised individuals and is no longer used in routine US schedules

The choice between IPV and OPV depends on local epidemiology, resources, and risk-benefit considerations. IPV is preferred in settings with low polio transmission and where safety from VAPP is prioritized.

Pharmacokinetics

Polio vaccine pharmacokinetics differ significantly between formulations:

IPV is administered intramuscularly or subcutaneously. The inactivated viral antigens are processed by antigen-presenting cells at the injection site and draining lymph nodes. Protective antibody levels develop within several weeks after the first dose, with peak immunity after completion of the primary series. Seroconversion rates exceed 95% after the full series. Antibody titers decline gradually over years but typically remain protective. Duration of immunity is considered lifelong for most individuals after a complete primary series, though a booster may be given for high-risk travel.

OPV is administered orally. The live attenuated virus replicates in the oropharyngeal and intestinal mucosa, with peak replication occurring within weeks post-administration. The virus is shed in stool for several weeks, which can provide secondary immunization of close contacts but also poses a risk of transmission of vaccine-derived poliovirus. Protective antibody levels develop within several weeks. Mucosal IgA antibodies provide local intestinal immunity that reduces viral shedding and transmission.

Neither vaccine is metabolized by hepatic enzymes. Excretion of IPV antigens occurs via normal immune clearance mechanisms. OPV virus is excreted in stool for weeks after administration.

Adverse effects

Adverse effects differ markedly between IPV and OPV:

IPV adverse effects

Common (mild and self-limited):

  • Local reactions: pain, erythema, and induration at injection site (up to 40%)
  • Low-grade fever (less common than with other vaccines)
  • Irritability and fussiness in infants

Rare:

  • Hypersensitivity reactions to vaccine components (streptomycin, polymyxin B, neomycin traces)
  • Anaphylaxis (extremely rare, approximately 1 per million doses)

IPV cannot cause poliomyelitis because the virus is inactivated.

OPV adverse effects

Common:

  • Generally well tolerated with minimal side effects
  • Mild diarrhea or fever (uncommon)

Serious:

  • Vaccine-associated paralytic poliomyelitis (VAPP): The most serious adverse effect, occurring in approximately 1 in 2.4 million doses for the first dose and 1 in 14 million for subsequent doses. Risk is highest in immunocompromised recipients and their close contacts. VAPP is clinically indistinguishable from wild-type poliomyelitis and can cause permanent paralysis.
  • Vaccine-derived poliovirus (VDPV): Circulating vaccine-derived poliovirus strains can emerge in areas with low vaccination coverage when OPV virus mutates and regains neurovirulence, causing outbreaks

Contraindications to further doses

  • Anaphylaxis to a previous dose or vaccine component
  • Development of VAPP after OPV (absolute contraindication to further OPV; switch to IPV if available)

The safety profile of IPV is excellent, making it the preferred formulation in countries that have eliminated wild poliovirus.

Contraindications and warnings

Absolute contraindications

For both IPV and OPV:

  • Severe allergic reaction (anaphylaxis) to a previous dose of polio vaccine
  • Severe allergic reaction to vaccine components:
  • IPV: streptomycin, polymyxin B, neomycin (trace amounts)
  • OPV: neomycin, streptomycin (if present in formulation)

Additional contraindications for OPV:

  • Immunodeficiency disorders (primary immunodeficiency, HIV/AIDS, malignancy, immunosuppressive therapy)
  • Household or close contacts who are immunocompromised (risk of transmission of vaccine virus)
  • Pregnancy (theoretical risk, though inadvertent administration is not an indication for termination)

Precautions

Moderate or severe acute illness: Postpone vaccination until recovery. Mild illness (e.g., upper respiratory infection) is not a contraindication.

Pregnancy: IPV may be given to pregnant women if indicated (e.g., travel to endemic area, outbreak exposure). OPV should be avoided in pregnancy when possible, though risk is theoretical.

Immunocompromised patients:

  • IPV is safe and should be used in immunocompromised individuals who require polio immunization
  • OPV is absolutely contraindicated due to risk of VAPP
  • Antibody response to IPV may be reduced in immunocompromised individuals; additional doses may be considered

Altered immunocompetence in household contacts: Use IPV instead of OPV to avoid transmission of vaccine virus to immunocompromised household members.

Warnings

  • OPV is no longer recommended in the United States and many other countries due to the risk of VAPP exceeding the risk of wild poliovirus infection
  • Healthcare providers should report suspected cases of VAPP to vaccine adverse event reporting systems
  • Breastfeeding is not a contraindication to either IPV or OPV administration

Drug interactions

Polio vaccine has minimal clinically significant drug interactions, but several considerations apply:

Immunosuppressive agents

Significant interaction:

  • Corticosteroids (high-dose or prolonged therapy), chemotherapeutic agents, biological immunomodulators (e.g., TNF inhibitors, rituximab), and other immunosuppressants may reduce antibody response to IPV
  • OPV is contraindicated in patients receiving immunosuppressive therapy due to risk of VAPP
  • If IPV is given during immunosuppression, serologic testing or revaccination after immune reconstitution may be considered
  • Short-term corticosteroids (less than 2 weeks), low-to-moderate doses, topical/inhaled steroids, and physiologic replacement doses do not typically impair vaccine response

Other vaccines

No significant interaction:

  • IPV can be administered simultaneously with other vaccines (e.g., DTaP, Hib, hepatitis B, MMR, varicella) at different injection sites without interference with immune response
  • OPV can be given with other live vaccines simultaneously or at any interval
  • No minimum interval required between IPV and other inactivated vaccines or live vaccines

Immune globulin and blood products

No interaction:

  • Unlike measles-containing vaccines, immune globulin and blood products do not interfere with the immune response to IPV or OPV
  • IPV and OPV can be administered at any time relative to immune globulin or blood product administration

Antibiotics

Minimal interaction:

  • Oral antibiotics do not significantly impair OPV immunogenicity, though theoretical concerns exist with broad-spectrum agents altering gut flora
  • Streptomycin, polymyxin B, or neomycin allergy is a contraindication due to trace amounts in vaccine formulations

Clinical approach: Whenever possible, avoid immunosuppressive agents around the time of vaccination. For patients on chronic immunosuppression requiring IPV, coordinate with specialists to optimize timing when feasible.

Clinical pearls

  • IPV vs. OPV key distinction: IPV cannot cause poliomyelitis (virus is inactivated), while OPV carries a risk of vaccine-associated paralytic poliomyelitis (VAPP) at approximately 1 in 2.4 million first doses. This risk is the primary reason IPV replaced OPV in the US routine schedule in 2000.
  • Mucosal immunity: OPV induces superior intestinal mucosal immunity (secretory IgA) compared to IPV, which primarily induces systemic immunity (IgG). This makes OPV more effective at interrupting person-to-person transmission, which is why it remains used in polio eradication campaigns in endemic regions.
  • Herd immunity with OPV: Vaccine virus from OPV is excreted in stool for weeks, potentially immunizing unvaccinated contacts. This secondary spread can be advantageous in outbreak settings but also creates risk of vaccine-derived poliovirus (VDPV) in under-immunized populations.
  • Immunocompromised patients: Always use IPV, never OPV, in immunocompromised patients or those with immunocompromised household contacts. VAPP risk is substantially elevated in these populations.
  • Adult vaccination: Most US-born adults completed childhood vaccination and do not need routine boosters. A single lifetime booster dose of IPV is recommended for adults traveling to polio-endemic countries (currently Afghanistan and Pakistan as of recent data) or areas with outbreaks.
  • Pregnancy: IPV is considered safe in pregnancy and should be given if indicated (e.g., travel to endemic area). OPV is theoretically contraindicated but inadvertent administration does not require pregnancy termination.
  • Vaccination schedule: Primary series typically begins in early infancy. Dosing follows standard childhood immunization schedules with appropriate intervals between doses.
  • Polio eradication context: Wild poliovirus type 2 was declared eradicated in 2015, and type 3 in 2019. Only wild poliovirus type 1 remains endemic. Most polio cases globally are now caused by vaccine-derived poliovirus from OPV, creating a paradox where the vaccine can perpetuate disease in under-immunized populations.
  • Combination vaccines: IPV is available in combination products (e.g., DTaP-IPV, DTaP-HepB-IPV) that simplify immunization schedules and reduce injection burden.
  • Post-exposure prophylaxis: Vaccination after exposure does not prevent disease from that exposure (incubation period 7-21 days) but does provide future protection. Close contacts of polio cases should be vaccinated if not fully immunized.
  • Laboratory workers: Those handling poliovirus specimens or working with live poliovirus strains should receive a primary series if unvaccinated and boosters as recommended by institutional guidelines.
  • True contraindications are rare: Anaphylaxis to prior dose or vaccine components is the primary absolute contraindication to IPV. Minor acute illness, mild antibiotic allergy, and breastfeeding are not contraindications.
Mnemonic

VAPP = Vaccine-Associated Paralytic Polio (remember OPV is oral and live, so it can cause paralysis; IPV is inactivated and safe)

Practice questions

1. A 4-month-old infant is brought to the clinic for routine vaccinations. The mother reports that the infant's 3-year-old sibling is currently receiving chemotherapy for acute lymphoblastic leukemia. Which of the following vaccines should be avoided in the infant at this visit?

Answer: E. OPV is contraindicated when household contacts are immunocompromised because the live attenuated virus is shed in stool for weeks and can be transmitted, potentially causing vaccine-associated paralytic poliomyelitis (VAPP) in the immunocompromised sibling. IPV should be used instead because it contains inactivated virus and poses no transmission risk. All other listed vaccines are inactivated or subunit vaccines and are safe to administer. This scenario tests the critical distinction between live and inactivated vaccines in households with immunocompromised individuals.

2. A 28-year-old aid worker is preparing for deployment to an area with an active polio outbreak. She received her childhood polio vaccinations according to the standard US schedule. Which of the following is the most appropriate recommendation?

Answer: C. A single lifetime booster dose of IPV is recommended for previously vaccinated adults traveling to polio-endemic countries or outbreak areas. This provides adequate protection without requiring a complete new series. OPV is no longer used in the US and is not recommended for travelers. Serologic testing is not routinely needed before vaccination. Childhood vaccination provides long-lasting immunity, but a booster enhances protection for high-risk exposure. This tests knowledge of adult polio vaccination recommendations for travel.

3. A 6-week-old infant develops flaccid paralysis 21 days after receiving oral polio vaccine as part of a mass immunization campaign. Stool culture grows poliovirus with genetic sequencing showing vaccine strain. The infant has no known medical history. What is the most likely diagnosis?

Answer: C. VAPP occurs when live attenuated virus in OPV reverts to neurovirulence and causes paralytic disease, typically within 4-40 days of vaccination. The isolation of vaccine-strain poliovirus confirms this diagnosis. VAPP occurs in approximately 1 per 2.4 million first doses and is the primary reason OPV was discontinued in the US. While undiagnosed immunodeficiency increases VAPP risk, the diagnosis is VAPP regardless of underlying immune status. Wild-type polio would show wild-strain virus, and Guillain-Barré typically follows a different time course without virus isolation. This tests the classic adverse effect of OPV.

Frequently asked questions

How does polio vaccine work?

Polio vaccine induces active immunity by stimulating antibody production against poliovirus types 1, 2, and 3. IPV (inactivated vaccine) is injected and produces systemic antibodies (IgG) that prevent viremia and paralytic disease. OPV (oral live vaccine) replicates in the gut, producing both systemic and mucosal antibodies (IgA) that block viral shedding and transmission. Both vaccines provide type-specific immunity lasting decades or lifelong after a complete primary series.

What are the side effects of polio vaccine?

IPV commonly causes mild local reactions like pain, redness, and swelling at the injection site, plus occasional low-grade fever. Serious side effects are extremely rare. OPV is generally well-tolerated but carries a risk of vaccine-associated paralytic poliomyelitis (VAPP) in approximately 1 per 2.4 million first doses, especially in immunocompromised individuals. OPV can also lead to vaccine-derived poliovirus outbreaks in under-immunized populations. IPV cannot cause polio because the virus is inactivated.

What is the difference between IPV and OPV?

IPV (inactivated polio vaccine) contains killed virus, is given by injection, cannot cause polio, and induces systemic immunity. OPV (oral polio vaccine) contains live attenuated virus, is given orally, can rarely cause vaccine-associated paralytic poliomyelitis (VAPP), and induces both systemic and mucosal immunity. IPV is used in the US and most developed countries for routine vaccination, while OPV is used in some endemic regions because it provides mucosal immunity that interrupts transmission and is easier to administer in mass campaigns.

Can adults get polio vaccine?

Yes, adults who were unvaccinated or incompletely vaccinated should receive IPV primary series. Most US-born adults completed childhood vaccination and do not need routine boosters. However, a one-time booster dose of IPV is recommended for previously vaccinated adults traveling to polio-endemic countries (currently Afghanistan and Pakistan) or areas with active outbreaks. Healthcare workers and laboratory personnel with potential poliovirus exposure may also need vaccination or boosters per institutional guidelines.

Is polio vaccine safe during pregnancy?

Yes, IPV is considered safe during pregnancy and should be given if indicated, such as for travel to polio-endemic areas or outbreak exposure. No adverse fetal effects have been documented. OPV is theoretically contraindicated in pregnancy due to the live virus, but inadvertent administration is not known to cause harm and is not an indication for pregnancy termination. If polio vaccination is needed during pregnancy, IPV is the preferred choice.

Conditions it is used for

Poliomyelitis preventionPoliovirus infection prevention
Measles-mumps-rubella vaccineDiphtheria-tetanus-pertussis vaccineHepatitis B vaccineHaemophilus influenzae type b vaccineVaricella vaccineRotavirus vaccinePneumocococcal vaccineMeningococcal vaccine

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: J07BF01WHO ATC/DDD index: J07BF03

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.